M&A Deal Summary

Amgen Acquires Horizon Therapeutics

On December 12, 2022, Amgen acquired life science company Horizon Therapeutics for 27.8B USD

Acquisition Highlights
  • This is Amgen’s 20th transaction in the Life Science sector.
  • This is Amgen’s largest (disclosed) transaction.
  • This is Amgen’s 1st transaction in Ireland.

M&A Deal Summary
Date 2022-12-12
Target Horizon Therapeutics
Sector Life Science
Buyer(s) Amgen
Deal Type Add-on Acquisition
Deal Value 27.8B USD

Target

Horizon Therapeutics

Dublin, Ireland
Horizon Therapeutics is a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and specialty business units. Horizon Therapeutics was founded in 2005 and is based in Dublin, Ireland.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Amgen

Thousand Oaks, California, United States
Category Company
Founded 1980
Sector Life Science
Employees26,700
Revenue 28.2B USD (2023)
DESCRIPTION
Entrance to Amgen's corporate campus in Thousand Oaks, California.
Entrance to Amgen's corporate campus in Thousand Oaks, California.

Amgen is a drug development company focused on discovering, developing, manufacturing and delivering human therapeutics. Amgen uses tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and people's lives. Amgen was founded in 1980 and is based in Thousand Oaks, California.

DEAL STATS #
Overall 21 of 21
Sector (Life Science) 20 of 20
Type (Add-on Acquisition) 20 of 20
Country (Ireland) 1 of 1
Year (2022) 2 of 2
Size (of disclosed) 1 of 20
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-08-04 ChemoCentryx

San Carlos, California, United States

ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. ChemoCentryx was incorporated in 1996 and is headquartered in San Carlos, California.

Buy $3.7B
Mergr

Product

Company

Legal